---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-25-000013"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:19:45.491285+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma reports FY2024 net loss $15.6M; cash $93.7M into 2027

## Summary
- Revenue $26.0M from Simcere license; no revenue in FY2023.
- R&D expense $29.3M (-$23.7M YoY) as Phase 2b asthma/atopic dermatitis trials completed.
- Net loss $15.6M ($0.28 EPS) vs $62.1M ($1.13) in FY2023.
- Phase 2 trials of rademikibart for acute asthma/COPD start Q2 2025; data expected H2 2026.
- CEO Barry Quart leads U.S.-centric shift; HQ relocated to San Diego, transition to domestic filer.

## SEC filing metadata
- accession: 0001835268-25-000013
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/0001835268-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000013/cntb-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-25-000013
- JSON: https://secwatch.observer/filing/0001835268-25-000013.json
- Plain text: https://secwatch.observer/filing/0001835268-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.